Healthcare & Pharmaceutical Market Research in Saudi Arabia

Riyadh is the regulatory and procurement capital of Saudi healthcare. SFDA headquarters and the MoH central directorate are both based in Riyadh, making it the primary center for pharmaceutical registration pathway research, formulary access studies, and government procurement committee mapping. Pharma research in Riyadh is shaped by the concentration of decision-making in public-sector channels and the Kingdom's largest specialist hospital cluster.

BioNixus runs healthcare market research in Riyadh across the major hospital networks: King Faisal Medical Complex (KFMC), King Fahad Medical City (KFMC-MC), and King Khalid University Hospital (KKUH). These institutions drive specialty prescribing in oncology, diabetes, cardiology, and rare disease — and house the KOLs whose formulary recommendations shape market access across the Kingdom.

For pharma teams conducting physician surveys in Riyadh, BioNixus provides verified HCP panels with specialty segmentation, CATI and online recruitment, and Arabic fieldwork with English deliverables. KOL depth interviews are conducted in-person or via video call depending on respondent preference and therapy area sensitivity.

Eastern Province healthcare research is shaped by two distinct dynamics: the Johns Hopkins Aramco Healthcare (JHAH) integrated health system serving Saudi Aramco employees and dependents, and the Dammam metro hospital system covering the broader Eastern Province population. JHAH operates a closed-network model with primary, specialty, and preventive care for one of the world's largest industrial workforces — a unique research segment for occupational health, metabolic disease, and workforce wellness studies.

Pharma research in the Eastern Province includes the Dammam metro hospital system: King Fahad University Hospital (KFUH-Dammam) and Dammam Medical Complex — both significant for specialty prescribing and government procurement in the Eastern region. The petrochemical workforce population creates distinct disease burden patterns relevant for cardiovascular, diabetes, and occupational medicine research.

BioNixus healthcare research in Al Khobar and Eastern Province covers HCP surveys, payer interviews, and medical device procurement committee research across both the Aramco-affiliated and public hospital networks. Eastern Province physician panels are segmented by hospital affiliation to reflect the distinct prescribing and formulary environments across JHAH, KFUH-Dammam, and Dammam Medical Complex.

Saudi Arabia's public hospital channel is shaped by NUPCO — the National Unified Procurement Company — which runs central tenders for pharmaceuticals, biologics, vaccines, and medical devices on behalf of Ministry of Health hospitals. For launch and access teams, understanding NUPCO committee criteria, tender calendar timing, and post-award uptake dynamics is as important as physician prescribing attitudes. BioNixus designs Saudi access research that connects both layers.

Typical NUPCO-aligned studies include competitive win/loss analysis among hospital pharmacists and procurement officers, physician switching intent in the 90 days after tender award, biosimilar substitution behaviour in MoH formularies, and pricing sensitivity relative to the SFDA-approved ex-factory price. These modules sit alongside standard HCP quantitative surveys and KOL depth interviews — giving commercial leadership a single evidence base for launch sequencing and tender strategy.

Private hospital channels in Jeddah and Riyadh operate outside NUPCO but remain relevant for specialty therapies, oncology, and high-cost biologics where insurance formulary decisions differ from MoH procurement. BioNixus segments Saudi samples by hospital affiliation — MoH, military, Aramco (JHAH), and private — so findings reflect the access environment each brand actually competes in. See our NUPCO tendering guide and healthcare market research hub for related resources.